Peter Salzmann - Aug 14, 2023 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Signature
/s/ Eva Renee Barnett, attorney-in-fact for Peter Salzmann
Stock symbol
IMVT
Transactions as of
Aug 14, 2023
Transactions value $
-$2,207,178
Form type
4
Date filed
8/16/2023, 04:11 PM
Previous filing
Aug 8, 2023
Next filing
Sep 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMVT Common Stock Sale -$1.96M -91.7K -8.12% $21.34 1.04M Aug 14, 2023 Direct F1, F2
transaction IMVT Common Stock Sale -$249K -11.3K -1.09% $22.04 1.03M Aug 14, 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On August 3, 2021, the holder was granted 570,613 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 4, 2021, of which the remaining 356,633 of these RSUs vested on August 3, 2023. As previously reported on a Form 4 filed on August 8, 2023, settlement was deferred with respect to 178,317 of the vested RSUs. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the remaining settlement of 178,317 of the RSUs and do not represent a discretionary sale by the holder.
F2 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.88 - $21.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
F3 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.88 - $22.18 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.